ゴーシェ病市場レポート：2030年までの動向、予測、競合分析

ゴーシェ病の動向と予測

世界のゴーシェ病市場は、2024年から2030年までのCAGRが2.1％で、2030年までに推定20億米ドルに達すると予想されます。この市場の主な促進要因は、遺伝子異常の有病率の増加、ゴーシェ病とその関連症状、診断に対する消費者の意識の高まり、治療オプションの容易な入手性です。世界のゴーシェ病市場の将来は、病院、専門クリニック、在宅ケア市場における機会によって有望視されています。

ゴーシェ病市場の洞察

Lucintelの予測では、1型は中枢神経系に影響を及ぼさず、非神経疾患であるため、予測期間中に最も高い成長が見込まれます。

病院が最大のセグメントであり続けると思われます。

アジア太平洋地域は、医療費の増加と大手企業の存在により、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答しています：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のゴーシェ病市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のゴーシェ病市場動向（2018-2023）と予測（2024-2030）
• 疾患の種類別の世界のゴーシェ病市場
  • タイプ1
  • タイプ2
  • タイプ3
  • その他
• 診断別の世界のゴーシェ病市場
  • 身体検査
  • 血液検査
  • 画像検査
  • 妊娠前スクリーニングと出生前検査
  • その他
• 治療別の世界のゴーシェ病市場
  • 手術
  • 薬
  • その他
• 最終用途別の世界のゴーシェ病市場
  • 病院
  • 専門クリニック
  • ホームケア
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のゴーシェ病市場
• 北米のゴーシェ病市場
• 欧州のゴーシェ病市場
• アジア太平洋ゴーシェ病市場
• その他地域ゴーシェ病市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 疾患の種類別の世界のゴーシェ病市場の成長機会
  • 診断別の世界のゴーシェ病市場の成長機会
  • 治療別の世界のゴーシェ病市場の成長機会
  • 最終用途別の世界のゴーシェ病市場の成長機会
  • 地域別の世界のゴーシェ病市場の成長機会
• 世界のゴーシェ病市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のゴーシェ病市場の能力拡大
  • 世界のゴーシェ病市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• ISU Abxis
• Johnson & Johnson
• Pfizer
• Protalix Biotherapeutics
• Sanofi S.A.
• Takeda Pharmaceutical

Gaucher Disease Trends and Forecast

The future of the global gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 2.1% from 2024 to 2030. The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

A more than 150-page report is developed to help in your business decisions.

Gaucher Disease by Segment

The study includes a forecast for the global gaucher disease by disease type, diagnosis, treatment, end use, and region.

Gaucher Disease Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

• Type 1
• Type 2
• Type 3
• Others

Gaucher Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

• Physical Exam
• Blood Tests
• Imaging Tests
• Preconception Screening and Prenatal Testing
• Others

Gaucher Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Surgery
• Medication
• Others

Gaucher Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Homecare
• Others

Gaucher Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Gaucher Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gaucher disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gaucher disease companies profiled in this report include-

• Isu Abxis
• Johnson & Johnson
• Pfizer
• Protalix Biotherapeutics
• Sanofi S.A.
• Takeda Pharmaceutical

Gaucher Disease Market Insights

Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Hospitals will remain the largest segment.

APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Features of the Global Gaucher Disease Market

Market Size Estimates: Gaucher disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gaucher disease market by various segments, such as by disease type, diagnosis, treatment, end use and region in terms of($B).

Regional Analysis: Gaucher disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different disease types, diagnosis, treatments, end uses, and region.s for the gaucher disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gaucher disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the gaucher disease market size?

Answer: The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030.

Q.2. What is the growth forecast for gaucher disease market?

Answer: The global gaucher disease market is expected to grow with a CAGR of 2.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the gaucher disease market?

Answer: The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

Q.4. What are the major segments for gaucher disease market?

Answer: The future of the gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key gaucher disease market companies?

Answer: Some of the key gaucher disease companies are as follows:

• ISU Abxis
• Johnson & Johnson
• Pfizer
• Protalix Biotherapeutics
• Sanofi S.A.
• Takeda Pharmaceutical

Q.6. Which gaucher disease market segment will be the largest in future?

Answer: Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Q.7. In gaucher disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gaucher disease market by disease type (type 1, type 2, type 3, and others), diagnosis (physical exam, blood tests, imaging tests, preconception screening and prenatal testing, and others), treatment (surgery, medication, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gaucher Disease Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Gaucher Disease Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Gaucher Disease Market by Disease Type
  • 3.3.1: Type 1
  • 3.3.2: Type 2
  • 3.3.3: Type 3
  • 3.3.4: Others
• 3.4: Global Gaucher Disease Market by Diagnosis
  • 3.4.1: Physical Exam
  • 3.4.2: Blood Tests
  • 3.4.3: Imaging Tests
  • 3.4.4: Preconception Screening and Prenatal Testing
  • 3.4.5: Others
• 3.5: Global Gaucher Disease Market by Treatment
  • 3.5.1: Surgery
  • 3.5.2: Medication
  • 3.5.3: Others
• 3.6: Global Gaucher Disease Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Homecare
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Gaucher Disease Market by Region
• 4.2: North American Gaucher Disease Market
  • 4.2.2: North American Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.3: European Gaucher Disease Market
  • 4.3.1: European Gaucher Disease Market by Disease Type: Type 1, Type 2, Type 3, and Others
  • 4.3.2: European Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.4: APAC Gaucher Disease Market
  • 4.4.1: APAC Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
  • 4.4.2: APAC Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.5: ROW Gaucher Disease Market
  • 4.5.1: ROW Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
  • 4.5.2: ROW Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Gaucher Disease Market by Disease Type
  • 6.1.2: Growth Opportunities for the Global Gaucher Disease Market by Diagnosis
  • 6.1.3: Growth Opportunities for the Global Gaucher Disease Market by Treatment
  • 6.1.4: Growth Opportunities for the Global Gaucher Disease Market by End Use
  • 6.1.5: Growth Opportunities for the Global Gaucher Disease Market by Region
• 6.2: Emerging Trends in the Global Gaucher Disease Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Gaucher Disease Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gaucher Disease Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: ISU Abxis
• 7.2: Johnson & Johnson
• 7.3: Pfizer
• 7.4: Protalix Biotherapeutics
• 7.5: Sanofi S.A.
• 7.6: Takeda Pharmaceutical